Amgen
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks
California
91320-1799
United States
Tel: 805-447-1000
Fax: 805-447-1010
Website: http://careers.amgen.com/
Email: talentacquisitioninquiries@amgen.com
About Amgen
We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.
We live the mission.
We win together.
We thrive on continual challenge.
Our team of 22,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.
At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.
Connect with us to explore how you can Win, Live, and Thrive at Amgen.
Defy Imagination
2434 articles about Amgen
-
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
9/12/2022
Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m. ET on Thursday, Sept. 15, 2022.
-
Lumakras®/Lumykras® (Sotorasib) Demonstrates Superior Progression-Free Survival Over Docetaxel in First Positive Phase 3 Trial of a KRAS G12C Inhibitor in Non-Small Cell Lung Cancer
9/11/2022
Amgen announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS®/LUMYKRAS® led to significantly superior progression-free survival and a significantly higher objective response rate in patients with KRAS G12C-mutated non small cell lung cancer, compared with intravenous chemotherapy, docetaxel.
-
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
9/8/2022
Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan, Italy, Sept. 7-10, 2022.
-
AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
9/8/2022
Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 13, 2022.
-
Amgen to Webcast Investor Call at ESMO 2022
9/7/2022
Amgen will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress at 1:30 p.m. ET on Monday, Sept. 12, 2022.
-
AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE
9/2/2022
Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m. ET on Thursday, September 8, 2022.
-
Amgen Announces Webcast of 2022 Citi Global Healthcare Conference
9/2/2022
Amgen will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m. ET on Wednesday, September 7, 2022.
-
Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival. -
AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
8/30/2022
Amgen (NASDAQ:AMGN) today announced that clinical and real-world data from across its inflammation portfolio, including both established treatments and pipeline assets, will be presented at the 31st European Academy of Dermatology and Venereology (EADV), taking place in Milan, Italy, Sept. 7-10, 2022.
-
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
8/30/2022
Amgen (NASDAQ: AMGN) today announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel.
-
New Amgen Data at ESC 2022 Show Long-Term LDL-C Lowering With Repatha® (Evolocumab) was Well-Tolerated for More Than 8 Years
8/29/2022
Amgen presented new compelling data from the Phase 3 FOURIER open label extension studies of Repatha® in adults with atherosclerotic cardiovascular disease during the Aug. 29 late-breaking Hot Line Session of the European Society of Cardiology Annual Meeting being held in Barcelona, Spain, and online.
-
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles. -
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
8/23/2022
Amgen (NASDAQ: AMGN) today announced positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS® (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
-
AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS
8/22/2022
Amgen (NASDAQ:AMGN) today announced the presentation of eight cardiovascular (CV) scientific research abstracts, including long-term and real-world evidence studies that add to the robust body of evidence demonstrating the efficacy and safety profile of Repatha® (evolocumab).
-
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer. -
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff. -
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
8/8/2022
Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
-
A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products. -
Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs. -
Amgen Data at WCLC 2022 Highlights Potential to Deliver Transformative Medicines for Historically Difficult-to-treat Lung Cancers
8/7/2022
Amgen announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer from August 6-9 in Vienna, Austria.